Ensuring timely antibody delivery in the face of supply chain challenges - contact us for solutions

Mouse Anti-Human IgA2-UNLB (A9604D2)

Cat. No.:
Purified Anti-Human IgA2 antibody for use in ELISA, flow cytometry, immunohistochemistry, western blot, ELISpot, separation, depletion, and multiplex assays.
Size Price (USD) Quantity
0.5 mg $165.00
More Information
Clone A9604D2
Isotype Mouse IgG1κ
Isotype Control Mouse IgG1-UNLB (15H6)
Specificity Human IgA2 Fc
Immunogen Purified human IgA2m(1) myeloma protein
Conjugate UNLB (Unconjugated)
Buffer Formulation Borate buffered saline, pH 8.2
Clonality Monoclonal
Concentration 0.5 mg/mL
Volume 1.0 mL
Recommended Storage 2-8°C
Applications ELISA – Quality tested 1-9
FLISA – Quality tested
ELISpot – Reported in literature 10
Flow Cytometry – Reported in literature 8,16
Immunohistochemistry-Frozen Sections – Reported in literature 8,11
Immunohistochemistry-Paraffin Sections – Reported in literature 12
Western Blot – Reported in literature 13-15
Multiplex – Reported in literature 17-19
Separation – Reported in literature 8
Depletion – Reported in literature 20

RRID Number AB_2796659
Gene ID 3494 (Human)
Gene ID Symbol IGHA2 (Human)
UniProt ID P01877 (Human)
UniProt Name IGHA2_HUMAN (Human)

Certificate of Analysis Lookup

Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view

Need help with this product?
or call 800.722.2255
  1. 1. Johnson S, Sypura WD, Gerding DN, Ewing SL, Janoff EN. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect Immun. 1995;63:3166-73. (ELISA)
  2. 2. Opstad NL, Daley CL, Thurn JR, Rubins JB, Merrifield C, Hopewell PC, et al. Impact of Streptococcus pneumoniae bacteremia and human immunodeficiency virus type 1 on oral mucosal immunity. J Infect Dis. 1995;172:566-70. (ELISA)
  3. 3. Islam D, Wretlind B, Ryd M, Lindberg AA, Christensson B. Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis. Infect Immun. 1995;63:2054-61. (ELISA)
  4. 4. Camacho MT, Outschoorn I, Kovácová E, Telléz A. Distribution of immunoglobulin G (IgG) and A (IgA) subclasses following Q fever vaccination with soluble phase I Coxiella burnetii extract. Vaccine. 2000;18:1773-7. (ELISA)
  5. 5. Ryan ET, Bridges EA, Crean TI, Gausia K, Hamadani JD, Aziz A, et al. Local production of anti-vibrio cholerae mucosal antibody in reproductive tract tissues after cholera. J Infect Dis. 2001;184:643-7. (ELISA)
  6. 6. Arnold M, Zacher T, Dechant M, Kalden JR, Doxiadis II, Spriewald BM. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol. 2004;65:1288-96. (ELISA)
  7. 7. Fasching CE, Grossman T, Corthésy B, Plaut AG, Weiser JN, Janoff EN. Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae. Infect Immun. 2007;75:1801-10. (ELISA)
  8. 8. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A2 class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. 2007;26:812-26. (ELISA, Sep, FC, IHC-FS)
  9. 9. Geisler WM, Morrison SG, Doemland ML, Iqbal SM, Su J, Mancevski A, et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. J Infect Dis. 2012;206:1836-43. (ELISA)
  10. 10. Carson PJ, Schut RL, Simpson ML, O'Brien J, Janoff EN. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J Infect Dis. 1995;172:340-5. (ELISPOT)
  11. 11. Senpuku H, Asano T, Matin K, Salam MA, Tsuha Y, Horibata S, et al. Effects of human interleukin-18 and interleukin-12 treatment on human lymphocyte engraftment in NOD-scid mouse. Immunology. 2002;107:232-42. (IHC-FS)
  12. 12. Islam D, Veress B, Bardhan PK, Lindberg AA, Christensson B. Quantitative assessment of IgG and IgA subclass producing cells in rectal mucosa during shigellosis. J Clin Pathol. 1997;50:513-20. (IHC-PS)
  13. 13. Batten MR, Senior BW, Kilian M, Woof JM. Amino acid sequence requirements in the hinge of human immunoglobulin A1 (IgA1) for cleavage by streptococcal IgA1 proteases. Infect Immun. 2003;71:1462-9. (WB)
  14. 14. Lewis MJ, Pleass RJ, Batten MR, Atkin JD, Woof JM. Structural requirements for the interaction of human IgA with the human polymeric Ig receptor. J Immunol. 2005;175:6694-701. (WB)
  15. 15. Lehoux S, Mi R, Aryal RP, Wang Y, Schjoldager KT, Clausen H, et al. Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals. Mol Cell Proteomics. 2014;13:3097-113. (WB)
  16. 16. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol. 2008;181:1767-79. (FC)
  17. 17. Arnold M, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens. 2008;72:60-6. (Multiplex)
  18. 18. Arnold M, Heinemann FM, Horn P, Ziemann M, Lachmann N, Mühlbacher A, et al. 16th IHIW: anti-HLA alloantibodies of the of IgA isotype in re-transplant candidates. Int J Immunogenet. 2013;40:17-20. (Multiplex)
  19. 19. Arnold M, Ntokou I, Doxiadis II, Spriewald BM, Boletis JN, Iniotaki AG. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int. 2014;27:253-61. (Multiplex)
  20. 20. Kitani A, Strober W. Differential regulation of Cα1 and Cα2 germ-line and mature mRNA transcripts in human peripheral blood B cells. J Immunol. 1994;153:1466-77. (Depletion)
See All References